AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Achaogen, Inc.

7000 Shoreline Court
Suite 371
South San Francisco, CA 94080
United States

Full Time Employees230

Key Executives

NameTitlePayExercisedYear Born
Mr. Blake WiseCEO & Director644kN/A1971
Dr. Kenneth J. HillanPres of R&D, Pres of Achaogen and Director771.6kN/A1961
Dr. Floyd E. Romesberg Ph.D.Principal Scientific Founder and AdvisorN/AN/AN/A
Dr. Nathaniel E. David A.B., Ph.D.Principal Entrepreneurial FounderN/AN/A1968
Mr. Tobin C. SchilkeChief Financial Officer & Principal Accounting OfficerN/AN/A1975
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Achaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Corporate Governance

Achaogen, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.